, /PRNewswire/ -- , the only provider of cloud-based insulin management Software as a Service (SaaS) solutions across the continuum of care, proudly announces significant new client partnerships in 1H 2024, reinforcing its position as the market leader in meeting the needs of the growing healthcare industry and diabetes technology market. Glytec's market leadership and momentum was on display in 1H 2024, adding 11 new deals, including , 3 health system expansions, and 6 renewals from satisfied clients with an average growth of 54%. "These deals add to why over 350 hospitals recognize Glytec's ability to address the top hospital challenges in 2024, including patient safety, profitability and cost of care, nurse and provider workflow, and revenue growth through increased patient throughput and reduced ICU length of stay," stated , Glytec CEO.
Hospitals are under increased pressure to improve patient safety and outcomes in the area of diabetes care, as demonstrated by the , an area for which Glytec has long been an advocate. Glytec's FDA-approved Glucommander solution and enhanced analytics have demonstrated a 6-8x Return-On-Investment (ROI) for clients as evidenced by studies showing an average 3.2 days reduction in ICU length of stay, a 99.
8 percent reduction in frequency of severe hypoglycemia, a 35-68 percent reduction in readmissions, and annual savings of over per 600 beds, amongst other independently verified findings. Glytec's industry-leading software addresses timely, .